PIK3CA and cancer: Several PI3K inhibitors have demonstrated promising activity in preclinical models of solid tumors, providing a rationale for their use in the clinic; thus, there are several currently in phase trials, with a handful having already received FDA and EMA approval for the treatment of several cancer types.